Deferoxamine Mesylate (CAS 138-14-7) Suppliers and Product Information

Deferoxamine mesylate is an iron chelator used to treat iron overload conditions. It is also used experimentally as a hypoxia mimetic and inhibitor of ferroptosis. The compound has shown neuroprotective effects in animal models of stroke, traumatic brain injury, and neurodegenerative diseases.

As an iron chelator, deferoxamine mesylate forms complexes with iron and aluminum ions, creating ferrioxamine and aluminoxamine respectively. These complexes are then excreted in urine and feces. The drug is primarily metabolized in plasma.

Frequently Asked Questions

Q: What are the main uses of deferoxamine mesylate?

A: Deferoxamine mesylate is primarily used as an iron chelating agent for treating acute iron poisoning and chronic iron overload conditions. It is also being investigated for its potential neuroprotective effects and use in treating reperfusion injuries.

Q: How does deferoxamine mesylate work?

A: Deferoxamine mesylate works by chelating iron and aluminum ions, forming complexes that can be excreted from the body. It also inhibits iron-dependent prolyl hydroxylases, which can prevent the degradation of hypoxia-inducible factor isoforms during normoxia.

Q: Are there any drug interactions with deferoxamine mesylate?

A: Yes, potentially hazardous interactions can occur with prochlorperazine, levomepromazine, and methotrimeprazine, which may lead to prolonged unconsciousness. It should also not be administered with blood.